Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.44 |
| ▸ | ACACB | O00763 | 2/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21838613 | 0.88 | NOTUM (0.60) | NOTUMPOLBACACBSLC6A9LMNA | |
| SCHEMBL22499991 | 0.86 | NOTUM (0.63) | NOTUMPOLBACACBSLC6A9LMNA | |
| SCHEMBL22499989 | 0.86 | NOTUM (0.63) | NOTUMPOLBACACBSLC6A9LMNA | |
| SCHEMBL21838630 | 0.83 | NOTUM (0.53) | NOTUMPOLBACACBSLC6A9LMNA | |
| SCHEMBL11544167 | 0.82 | NOTUM (0.57) | NOTUMPOLBACACBLMNAHTT | |
| SCHEMBL20063904 | 0.80 | NOTUM (0.57) | NOTUMPOLBSCN9AACACBALDH1A1 | |
| SCHEMBL1337159 | 0.79 | CACNA1B (0.51) | NOTUMPOLBACACBSLC6A9LMNA | |
| SCHEMBL20063477 | 0.78 | SCN9A (0.50) | NOTUMPOLBSCN9AACACBLMNA | |
| SCHEMBL20063903 | 0.78 | NOTUM (0.51) | NOTUMPOLBSCN9AACACBLMNA | |
| SCHEMBL20095505 | 0.78 | NOTUM (0.52) | NOTUMPOLBSCN9AACACBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | NOTUM 3035/4885POLB 4679/4885SCN9A 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.